TY - JOUR
T1 - Synthesis, biological evaluation, and molecular modeling of nitrile-containing compounds
T2 - exploring multiple activities as anti-Alzheimer agents
AU - Silva, Daniel
AU - Mendes, Eduarda
AU - Summers, Eleanor J.
AU - Neca, Ana
AU - Jacinto, Ana C.
AU - Reis, Telma
AU - Agostinho, Paula
AU - Bolea, Irene
AU - Jimeno, M. Luisa
AU - Mateus, M. Luisa
AU - Oliveira-Campos, Ana M. F.
AU - Unzeta, Mercedes
AU - Marco-Contelles, José
AU - Majekova, Magdalena
AU - Ramsay, Rona R.
AU - Carreiras, M. Carmo
N1 - Funding: EC COST Actions D34 and CM1103 for Short-term Scientific Mission funding (EM, DS, MM); the School of Biology at the University of St. Andrews (EJS, RRR); the Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa (AN, ACJ, TR, MCC); FCT, the Portuguese Foundation for Science and Technology (Project PTDC/SAU-NEU/64151/2006 (MCC), and project grant (DS) Vega 2/0127/18 and the contract No. APVV-15-0455 of Slovak Research and Development Agency (MM).
PY - 2019/8/30
Y1 - 2019/8/30
N2 - Based on the monoamine oxidase (MAO) inhibition properties of
aminoheterocycles with a carbonitrile group we have carried out a
systematic exploration to discover new classes of carbonitriles endowed
with dual MAO and AChE inhibitory activities, and Aβ anti‐aggregating
properties. Eighty‐three nitrile‐containing compounds, 13 of which are
new, were synthesized and evaluated. in vitro screening revealed that 31,
a new compound, presented the best lead for trifunctional inhibition
against MAO A (0.34 μM), MAO B (0.26 μM), and AChE (52 μM), while 32
exhibited a lead for selective MAO A (0.12 μM) inhibition coupled to
AChE (48 μM) inhibition. Computational analysis revealed that the
malononitrile group can find an advantageous position with the aromatic
cleft and FAD of MAO A or MAO B. However, the total binding energy can
be handicapped by an internal penalty caused by twisting of the ligand
molecule and subsequent disruption of the conjugation (32 in MAO B compared to the conjugated 31).
Conjugation is also important for AChE as well as the hydrophilic
character of malononitrile that allows this group to be in close contact
with the aqueous environment as seen for 83. Although the effect of 31 and 32 against Aβ1–42, was very weak, the effect of 63 and 65, and of the new compound 75, indicated that these compounds were able to disaggregate Aβ1–42 fibrils. The most effective was 63,
a (phenylhydrazinylidene)propanedinitrile derivative that also
inhibited MAO A (1.65 μM), making it a potential lead for Alzheimer's
disease application.
AB - Based on the monoamine oxidase (MAO) inhibition properties of
aminoheterocycles with a carbonitrile group we have carried out a
systematic exploration to discover new classes of carbonitriles endowed
with dual MAO and AChE inhibitory activities, and Aβ anti‐aggregating
properties. Eighty‐three nitrile‐containing compounds, 13 of which are
new, were synthesized and evaluated. in vitro screening revealed that 31,
a new compound, presented the best lead for trifunctional inhibition
against MAO A (0.34 μM), MAO B (0.26 μM), and AChE (52 μM), while 32
exhibited a lead for selective MAO A (0.12 μM) inhibition coupled to
AChE (48 μM) inhibition. Computational analysis revealed that the
malononitrile group can find an advantageous position with the aromatic
cleft and FAD of MAO A or MAO B. However, the total binding energy can
be handicapped by an internal penalty caused by twisting of the ligand
molecule and subsequent disruption of the conjugation (32 in MAO B compared to the conjugated 31).
Conjugation is also important for AChE as well as the hydrophilic
character of malononitrile that allows this group to be in close contact
with the aqueous environment as seen for 83. Although the effect of 31 and 32 against Aβ1–42, was very weak, the effect of 63 and 65, and of the new compound 75, indicated that these compounds were able to disaggregate Aβ1–42 fibrils. The most effective was 63,
a (phenylhydrazinylidene)propanedinitrile derivative that also
inhibited MAO A (1.65 μM), making it a potential lead for Alzheimer's
disease application.
KW - Nitrile-containing compounds
KW - Alzheimer's disease
KW - MAO inhibitors
KW - Cholinesterase inhibitors
KW - Aβ1-42 disaggregating agents
KW - In silico study
U2 - 10.1002/ddr.21594
DO - 10.1002/ddr.21594
M3 - Article
SN - 1098-2299
VL - Early View
JO - Drug Development Research
JF - Drug Development Research
M1 - DDR-19-0121.R1
ER -